Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Published:2024-07 Issue: Volume: Page:102164
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Silberg Matteo,Krabbe Laura-Maria,Bögemann Martin^ORCID,Schrader Andres Jan,Tully Karl^ORCID,Schlack Katrin^ORCID

Publisher

Elsevier BV

Reference29 articles.

1. European association of urology guidelines on renal cell carcinoma: the 2022 update;Ljungberg;Eur Urol,2022

2. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma;Gorin;Eur Urol Oncol,2022

3. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;Powles;Lancet Oncol,2022

4. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

5. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP